Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Phase 2 trial results, published in 2023 in the New England Journal of Medicine (Jastreboff et al., NEJM 2023), demonstrated that participants receiving the highest dose of retatrutide lost an average of approximately 24% of their body weight over 48 weeks a finding that attracted considerable attention from the medical and scientific communities
These results should not be interpreted as evidence of superiority over approved treatments
GBD 2019)
GPhC 2224423 Curated nutrition Clinician-selected nutrition to work alongside treatment: protein, fibre and micronutrients matched to a GLP-1 routine
Switching between semaglutide and tirzepatide is increasingly common, especially for researchers who have plateaued on one compound and want to explore whether a dual agonist (GLP-1/GIP) provides additional benefits
US$ 29.49
US$ 28.29
US$ 25.40
US$ 23.46
